home / stock / adap / adap quote
Last: | $1.065 |
---|---|
Change Percent: | 0.47% |
Open: | $1.06 |
Close: | $1.06 |
High: | $1.095 |
Low: | $1.05 |
Volume: | 309,438 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.065 | $1.06 | $1.06 | $1.095 | $1.05 | 309,438 | 04-26-2024 |
$1.06 | $1.05 | $1.06 | $1.0992 | $1.04 | 565,527 | 04-25-2024 |
$1.08 | $1.14 | $1.08 | $1.15 | $1.07 | 777,793 | 04-24-2024 |
$1.14 | $1.04 | $1.14 | $1.16 | $1 | 1,131,087 | 04-23-2024 |
$1.01 | $0.99 | $1.01 | $1.08 | $0.94 | 694,255 | 04-22-2024 |
$0.9767 | $0.9201 | $0.9767 | $1.1 | $0.920001 | 1,482,450 | 04-19-2024 |
$0.8984 | $0.9676 | $0.8984 | $0.9893 | $0.8721 | 3,345,633 | 04-18-2024 |
$0.987 | $1.02 | $0.987 | $1.045 | $0.9301 | 1,222,265 | 04-17-2024 |
$1.03 | $1.05 | $1.03 | $1.06 | $0.9801 | 1,224,206 | 04-16-2024 |
$1.05 | $1.2 | $1.05 | $1.21 | $1.05 | 1,324,308 | 04-15-2024 |
$1.16 | $1.2 | $1.16 | $1.2799 | $1.13 | 3,079,437 | 04-12-2024 |
$1.29 | $1.28 | $1.29 | $1.34 | $1.26 | 882,268 | 04-11-2024 |
$1.27 | $1.33 | $1.27 | $1.33 | $1.25 | 1,514,980 | 04-10-2024 |
$1.37 | $1.36 | $1.37 | $1.405 | $1.35 | 718,236 | 04-09-2024 |
$1.36 | $1.4 | $1.36 | $1.41 | $1.33 | 1,025,092 | 04-08-2024 |
$1.37 | $1.39 | $1.37 | $1.42 | $1.32 | 1,205,337 | 04-05-2024 |
$1.35 | $1.41 | $1.35 | $1.45 | $1.35 | 777,369 | 04-04-2024 |
$1.38 | $1.4 | $1.38 | $1.42 | $1.35 | 1,636,265 | 04-03-2024 |
$1.4 | $1.46 | $1.4 | $1.46 | $1.36 | 1,148,290 | 04-02-2024 |
$1.47 | $1.55 | $1.47 | $1.55 | $1.45 | 1,334,215 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4 th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18 th Investor Day Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. -...
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with ...
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial r...